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Abstract Rheumatoid arthritis (RA) is a chronic autoimmune
disease associated with changes in several hormones and met-
abolic peptides. Crosstalk between these factors and the im-
mune system may be important for homeostasis during in-
flammation. Here, we studied the levels of hormones, meta-
bolic peptides, and nutrients in individuals at risk for develop-
ing RA (at risk). In total, 18 hormones, metabolic peptides,
and nutrients were measured in fasting serum samples from 45
autoantibody-positive individuals at risk, 22 RA patients, and
16 healthy subjects. Triglyceride (TG) levels were also mea-
sured in an independent validation cohort of 32 individuals at
risk, 20 early arthritis patients, and 20 healthy controls. We
found an elevated TG level in individuals at risk and significant-
ly higher TG levels in RA patients compared to healthy controls.
These results were confirmed in the validation cohort. Similarly,
free fatty acid (FFA) levels showed an increase in individuals at
risk and were significantly higher in RA patients compared to
healthy controls. In RA patients, FFA levels were positively
correlated with disease activity. Pancreatic polypeptide (PP)
and norepinephrine levels were highly significantly increased
in individuals at risk and RA patients compared to healthy con-
trols. TG and FFA levels are increased in RA patients and pos-
itively correlated with disease activity parameters. The results
presented here suggest a role for FFAs in the pathogenesis of
RA. Furthermore, PP and norepinephrine may be a biomarker
that could assist in the identification of individuals at risk.
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SJC28 Swollen joint count of 28 joints
TG Triglyceride
TJC28 Tender joint count of 28 joints
TSH Thyroid stimulating hormone
UA Unclassified arthritis
VAS Visual analogue scale
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease af-
fecting approximately 1 % of the population worldwide. Various
hormones and metabolic peptides play a role in RA, suggesting
crosstalk between the endocrine system and immunity [1]. RA is
associated with an increased incidence in cardiovascular morbid-
ity and mortality [2, 3]. Previously, elevated triglyceride (TG)
levels have been demonstrated in RA patients compared to
healthy controls [4, 5]. TGs can be synthesized from glycerol
and free fatty acids (FFAs) by a condensation reaction, and be-
cause of the relative increase in adipose tissue, FFAs are elevated
in obesity [6]. An earlier study has shown an increase in FFA
levels in the presence of ametabolic syndrome in established RA
patients as well as in controls [7]. Previously, it has also been
reported that insulin levels are higher in RA patients compared to
controls [7]. This finding suggests a relationship between meta-
bolic peptides and increased insulin resistance, which was
thought to increase cardiovascular morbidity in patients with
RA. Although the authors did not find a correlation with FFAs
and coronary atherosclerosis, the contribution of FFAs to athero-
sclerosis may be independent of insulin resistance [7]. These
observations suggest that apart from classical risk factors for
cardiovascular disease (CVD), the secretion of metabolic pep-
tides may also play an important role in the increased cardiovas-
cular risk profile in RA.
It has previously been hypothesized that there may be a link
between the gastrointestinal and the immune system via an
interaction between cytokines and gut hormones. Peptide
YY (PYY), member of the pancreatic polypeptide (PP) family,
is one of the gut hormones, which could play a role in RA. The
levels of PP, one of the other metabolic factors produced by
the pancreas, are also increased in established RA patients
compared to healthy controls [8].
In recent years, it has been recognized that the development of
clinical signs and symptoms of RA is preceded by a phase char-
acterized by systemic abnormalities including the presence of
autoantibodies [9–11] and increased serum levels of C-reactive
protein (CRP) [12] in the peripheral blood of individuals at risk
for RA. Smoking and overweight further increase the risk of
development of arthritis [13]. The underlying mechanisms are
however not fully understood. To provide more insight into a
possible role of hormones and metabolic peptides in the patho-
genesis as well as the increased risk for cardiovascular disease in
RA, we describe the hormone, peptide, and nutrient levels in a
unique cohort of individuals at risk for developing RA. The
levels were compared to those found in patients with established
RA and healthy controls.
Patient and methods
Study subjects
Twenty-two patients with active RA, 45 individuals at risk for
developing RA, and 16 healthy controls were included in the first
part of this study. The individuals at risk for RA had arthralgia
and/or a positive family history for RA, without any evidence of
arthritis upon thorough physical examination. Theywere positive
for IgM rheumatoid factor (IgM-RF) and/or anticitrullinated pro-
tein antibodies (ACPAs). These individuals at risk were charac-
terized by the presence of systemic autoimmunity associatedwith
RA (phase c according to [14]) with or without environmental
risk factors (phase b + c according to [14]), with or without
symptoms but without clinical arthritis (phase d according to
[14]) and with or without genetic risk factors (phase a + b + c
according to [14]). IgM-RFwasmeasured using IgM-RF ELISA
from Hycor Biomedical, Indianapolis, IN (ULN 49 IU/ml).
ACPA was measured using anti-CCP2 Elisa CCPlus
(Eurodiagnostica, Nijmegen, the Netherlands (ULN 25 kAU/L)).
RA patients fulfilled the 2010 ACR/EULAR classification
criteria [15, 16] and had active disease defined as DAS28 >2.6
and at least one swollen joint. All RA patients were treated
with non-steroidal anti-inflammatory drugs (NSAIDs) and/or
disease-modifying antirheumatic drugs (DMARDs) and were
biological naive. RA patients and the individuals at risk for
RAwere recruited via the outpatient clinic of the department
of Clinical Immunology and Rheumatology of the Academic
Medical Center, Amsterdam, the Netherlands. We included
healthy controls, matched for gender and age, without joint
complaints, history of clinical evident arthritis, and who were
not known with other systemic inflammatory disease for
which immunosuppressive therapy was needed; they were
negative for IgM-RF and ACPA. The controls were also re-
cruited in the Academic Medical Center, Amsterdam, the
Netherlands, via advertisements.
We used another cohort to validate our findings in the test
cohort in order to limit the chance on significant results by
coincidence. We included an independent validation cohort,
consisting of 32 individuals at risk for RA (arthralgia and
elevated IgM-RF and/or ACPA serum levels without clinical-
ly manifest arthritis), 20 early arthritis patients with disease
duration <6 months (n = 16 RA and n = 4 unclassified arthritis
(UA)), and 20 age- and gender-matched healthy controls.
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Patients were classified as UA in the absence of fulfillment of
disease-specific criteria, but they had elevated serum levels of
RA-specific autoantibodies (IgM-RF and/or ACPA). The RA
and UA patients were biologically naive.
All subjects were included at the outpatient clinic of the de-
partment of Clinical Immunology and Rheumatology of the
Academic Medical Center, Amsterdam, the Netherlands. The
study was performed according to the principles of the
Declaration of Helsinki, approved by the institutional review
board of the Academic Medical Center (2010_327#B2011135),
registered in TheNetherlands National Trial Register/Nederlands
Trial Register (NTR2833), and all study subjects gave written
informed consent.
Study procedures
After enrollment, the individuals at risk for developing RA
were followed annually for arthritis development, which was
the endpoint of the study. Patients with established RA and
healthy controls had one study visit. Overnight fasting blood
samples were collected between 9 and 10 a.m. at baseline and
again when arthritis developed in the at-risk population.
Samples were directly stored on ice, centrifuged, aliquotted,
and frozen at −80° within 30 min after bleeding of the subject.
Catecholamines were determined in tubes containing
EGTA/glutathione and glucagon using tubes containing
aprotinin.
The hormones and peptides tested are described in
Supplementary Table 1. Lipid levels (total cholesterol, high
density lipoprotein (HDL)-cholesterol, low density lipopro-
tein (LDL)-cholesterol, and TG) were measured using stan-
dard laboratory techniques. All hormone measurements, ex-
cept for adrenocorticotropic hormone (ACTH), cortisol, and
insulin, were performed in duplicate. The mean of these du-
plicate means were used for the analysis. The validation co-
hort was used to confirm the results obtained for lipid levels.
The following clinical and disease activity parameters were
obtained during the study visits: age, sex, body mass index
Table 1 Characteristics of the study subjects
RA (n = 22) At risk for RA (n = 45) Healthy control (n = 16) P value
Age (years) 60 (46–64) 50 (41–55) 50 (43–59) 0.048
Female (n (%)) 15 (68) 32 (71) 9 (56) 0.58
BMI (kg/m2) 25.0 (21.7–27.8) 25.8 (23.4–30.1) 23.8 (22.5–25.7) 0.20
Alcohol use (n (%)) 11 (50) 22 (49) 13 (81) 0.08
Current smoker (n (%)) 4 (18) 14 (31) 1 (6) 0.14
Cigarettes/daya 18 (13–25) 10 (5–15) 20 (20–20) 0.12
Pack yearsa 40.5 (27.5–50.5) 12.5 (10.0–25.0) 34 (34.0–34.0) 0.09
IgM-RF positive (n (%)) 19 (86) 32 (71) 0 (0) NA
IgM-RF titer (kU/l)b 277 (144–360) 126 (89–261) NA NA
ACPA positive (n (%)) 17 (77) 29 (64) 0 (0) NA
ACPA titer (kAU/L)b 379 (104–982) 375 (109–1003) NA NA
Disease duration (months) 10 (2–85) NA NA NA
VAS GDA (mm) 47 (27–64) 31 (15–54) 0 (0–0) NA
TJC28 (n) 5 (4–8) 1 (0–3) 0 (0–0) NA
SJC28 (n) 2 (2–5) 0 (0–0) 0 (0–0) NA
ESR (mm/h) 15 (8–27) 5 (2–9) 2 (2–5) NA
CRP (mg/l) 4.6 (2.0–10.3) 1.4 (0.8–4.0) 1.4 (0.6–3.5) NA
DAS28 4.32 (3.69–4.82) NA NA NA
NSAIDs (n (%)) 10 (46) 15 (33) 0 (0) NA
Corticosteroids (n (%)) 6 (27) 0 (0) 0 (0) NA
Methotrexate (n (%)) 17 (77) 0 (0) 0 (0) NA
HCQ (n (%)) 3 (14) 0 (0) 0 (0) NA
Data presented as median (interquartile range) or number (percentage). P values for Kruskal-Wallis test for continuous variables and Pearson chi-square
test for categorical variables. P < 0.05 is considered statistically significant
IgM-RF IgM rheumatoid factor, RA rheumatoid arthritis, BMI body mass index, ACPA anticitrullinated protein antibodies, VAS GDA patient visual
analog scale (range 0–100 mm) global disease activity, TJC28 tender joint count of 28 joints, SJC28 swollen joint count of 28 joints, ESR erythrocyte
sedimentation rate, CRP C-reactive protein, HCQ hydroxychloroquine, NA not applicable
a Only in smokers
b Only in positive patients or individuals
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(BMI), alcohol use, smoking status, IgM-RF and ACPA sta-
tus, disease duration, use of NSAIDs, and/or DMARDs.
Patient visual analog scale for global disease activity (VAS
GDA) of 0–100 mm, tender joint count of 28 joints
(TJC28), swollen joint count of 28 joints (SJC28), erythrocyte
sedimentation rate (ESR; in mm/h), C-reactive protein (CRP;
mg/L), and disease activity score evaluated in 28 joints
(DAS28) were also measured. In individuals who developed
arthritis, an additional visit was performed and all clinical and
disease activity parameters mentioned above were assessed,
including a 68 joint score to confirm the presence of arthritis.
Statistical analysis
Data are presented as median (IQR) unless otherwise indicat-
ed. Differences between study groups were analyzed using
Kruskal-Wallis or Mann-Whitney U test where appropriate.
We considered a p value of <0.05 as significant in this explor-
atory study. The differences found in this exploratory study
should be evaluated in future studies. Categorical data were
analyzed using chi-square test or, if more appropriate, Fisher’s
exact test. Correlations between variables were analyzed using
Spearman’s rank correlation coefficient. Statistical analysis
was performed using IBM SPSS Statistics 18 (SPSS Inc.,
Chicago, IL).
Results
The characteristics of the study subjects in the first part of this
study are summarized in Table 1. Three of the 45 individuals
at risk for developing RA (referred to as Bat-risk^ individuals)
(7 %) developed RA during follow up after 18 (16–22)
months. The RA patients were significantly older compared
to at-risk individuals and healthy controls. Healthy controls
were matched for age with the at-risk individuals rather than
the RA patients, because on average age is higher in RA
patients than in at-risk individuals. Supplementary Table 2
shows the characteristics of the study subjects in the indepen-
dent validation cohort. From the 32 at-risk individuals, 10
subjects developed arthritis and 22 individuals did not develop
arthritis after 5 years of follow up.
Most hormone levels are comparable in at-risk
individuals, patients with RA and healthy controls
Figure 1 and Table 2 show the hormone levels and peptide
levels in at-risk individuals, patients with RA, and healthy
controls. There were significantly higher norepinephrine
levels in at-risk individuals (3.02 (2.24–4.15) nmol/L) com-
pared to RA patients (2.45 (1.51–3.26) nmol/L) and healthy
controls (2.15 (1.49–2.71) nmol/L; P = 0.017). The norepi-
nephrine levels did not correlate with clinical and laboratory
disease parameters in either RA patients or in at-risk individ-
uals. The epinephrine levels were not different between the
three groups. The levels of ACTH, cortisol, and cortisol/IL-6
ratio were also on average comparable between the three
groups. IL-6 levels were higher in both individuals at risk
(25.1 (3.8–54.5) pg/ml) and RA patients (27.7 (9.3–80.9)
pg/ml) compared to healthy controls (7.5 (0.9–66.7) pg/ml;
P = 0.23). The sex hormones estradiol, follicle stimulating
hormone (FSH), and luteinizing hormone (LH) were compa-
rable between the three groups. PRL levels were also similar
in the at-risk individuals and RA patients compared with
healthy controls. Similarly, the neuroendocrine hormones
growth hormone (GH) and thyroid stimulating hormone
(TSH) were comparable between the groups.
FFAs are elevated in at-risk individuals and correlated
with disease activity parameters
In the test cohort, we found higher TG levels in at-risk indi-
viduals and significantly higher TG levels in RA patients com-
pared to healthy controls (0.94 (0.72–1.15) mmol/L, 1.03
(0.75–1.29) mmol/L, and 0.70 (0.59–1.02) mmol/L, respec-
tively; P = 0.11). We could confirm these findings in the
independent validation cohort and found significantly in-
creased TG levels in 20 early arthritis patients (consisting of
RA and UA patients) compared to 20 healthy controls
matched for age and gender (1.05 (0.65–1.54) mmol/L and
0.80 (0.48–0.90), respectively; P = 0.036 (Fig. 2). Moreover,
in this validation cohort of 32 at-risk individuals, we observed
significantly higher TG levels in baseline serum of 10 individ-
uals who developed arthritis during follow up (1.47 (1.12–
1.91) mmol/L) compared to 22 individuals who did not devel-
op arthritis (1.01 (0.68–1.31) mmol/L) (P = 0.030).
In line with this, we found a trend toward increased FFA
levels in the at-risk individuals (0.53 (0.40–0.59) mmol/L) and
significantly higher levels in RA patients (0.59 (0.47–0.65)
mmol/L) compared to healthy controls (0.40 (0.35–0.50)
mmol/L; P = 0.024), independent of gender. The association
of the FFA levels in the three different groups was not con-
founded by age, BMI, current smoking, or other variables
measured (using regression analysis). Using the reference up-
per limit of 0.44 mmol/L as cutoff, 30 (67 %) at-risk individ-
uals had elevated FFA levels compared to 18 (82 %) RA
patients and 5 (31 %) healthy controls (P = 0.005).
Interestingly, the FFA levels correlated in RA patients with
TJC28 (r = 0.48 and P = 0.022), CRP (r = 0.47 and
P = 0.029), and DAS28 (r = 0.53 and P = 0.012) and a trend
toward a positive correlation with VAS GDA (r = 0.39 and
P = 0.07) and SJC28 (r = 0.41 and P = 0.06) was seen (Fig. 3).
In the at-risk individuals without arthritis, we did not observe a
correlation between FFA levels and clinical and laboratory
disease parameters. The PP levels were significantly higher
both in at-risk individuals (31 (21–45) pmol/L) and RA
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patients (34 (23–58) pmol/L) compared to healthy controls
(10 (6–27) pmol/L); P = 0.003. The PP levels did not correlate
with clinical and laboratory disease parameters in either RA
patients or in at-risk individuals.
Because of the small number of the at-risk individuals de-
veloping arthritis in this study, no conclusions can be drawn
on the role of these hormones and peptides in the risk of
developing arthritis. The values for these individuals are de-
scribed in Table 3.
Discussion
The results presented here show the levels of hormones and
metabolic peptides in a cohort of individuals at risk of devel-
oping RA, patients with established RA, and healthy controls.
We confirmed that TG and FFA levels are elevated in
established RA, and we found that the FFA levels correlate
with disease activity parameters. Of importance, we also
found a clear trend toward elevated TG and FFA levels in
individuals at risk for RA. Thus, the changes in lipid profile
appear to precede the development of clinically manifest RA.
There were significantly higher TG levels in baseline serum of
subjects who developed arthritis during follow up compared
to those who did not. PP levels were also highly significantly
increased in both individuals at risk for RA and established
RA patients. Although it has previously been suggested that
the balance between hormones and metabolic peptides on the
one hand and proinflammatory and anti-inflammatory cyto-
kines on the other could play an important role in inflamma-
tion [1], most other hormones and peptides were comparable
between the three study groups described here.
Table 2 Endocrine hormone and metabolic peptide levels in at-risk individuals, patients with RA, and healthy controls
RA (n = 22) Healthy controls (n = 16) P valueb At risk for RA (n = 45) P valuec
Catecholamines
Epinephrine (nmol/L) 0.17 (0.03–0.34) 0.15 (0.06–0.18) 0.47 0.17 (0.06–0.26) 0.64
NE (nmol/L) 2.45 (1.51–3.26) 2.15 (1.49–2.71) 0.41 3.02 (2.24–4.15) 0.017
HPA axis response
ACTH (ng/L)a 19.3 (12.1–26.9) 18.7 (13.4–23.6) 0.97 19.2 (12.7–27.5) 0.99
Cortisol (nmol/L)a 349 (246–457) 319 (288–366) 0.87 323 (222–422) 0.96
IL-6 (pg/ml) 27.7 (9.3–80.9) 7.5 (0.9–66.7) 0.22 25.1 (3.8–54.5) 0.23
Cortisol/IL-6 ratioa 13.8 (3.0–16.9) 16.7 (3.2–93.0) 0.48 11.4 (5.3–35.1) 0.80
Sex hormones
Estradiol (nmol/L) 0.03 (0.02–0.08) 0.05 (0.03–0.09) 0.23 0.04 (0.02–0.08) 0.52
FSH (IU/L) 15.1 (7.2–49.7) 6.4 (3.8–57.3) 0.30 8.0 (3.2–71.7) 0.60
LH (IU/L) 12.4 (4.9–26.2) 3.9 (3.0–27.7) 0.28 7.1 (3.9–33.6) 0.45
Prolactin (μg/L) 9 (7–17) 10 (7–12) 0.73 9 (7–13) 0.95
Other hormones
GH (mU/L) 2.10 (1.00–2.90) 1.35 (0.20–3.00) 0.17 1.1 (0.50–3.20) 0.22
TSH (mU/L) 1.85 (1.20–2.70) 1.90 (1.60–2.15) 0.80 1.55 (1.25–2.50) 0.51
Peptides
TGs (mmol/L) 1.03 (0.75–1.29) 0.70 (0.59–1.02) 0.036 0.94 (0.72–1.15) 0.11
FFAs (mmol/L) 0.59 (0.47–0.65) 0.40 (0.35–0.50) 0.011 0.53 (0.40–0.59) 0.024
Glucagon (ng/L) 87 (75–107) 82 (68–94) 0.15 89 (74–99) 0.34
Glucose (mmol/L) 5.1 (4.8–5.4) 5.2 (4.8–5.4) 0.89 5.2 (4.8–5.4) 0.77
Insulin (pmol/L) 78 (41–94) 54 (32–62) 0.13 57 (43–100) 0.32
PP (pmol/L) 34 (23–58) 10 (6–27) 0.004 31 (21–45) 0.003
Data presented as median (interquartile range). P# values for Mann-Whitney U test (between RA patients and healthy controls) and P## values for
Kruskal-Wallis test (between all the three groups). P value <0.05 or after Bonferroni correction <0.0028 is considered statistically significant after
Bonferroni correction
RA rheumatoid arthritis,NE norepinephrine,HPA axis response hypothalamic-pituitary-adrenal axis response, ACTH adrenocorticotropic hormone, IL-6
interleukin 6, FSH follicle stimulating hormone, LH luteinizing hormone; GH growth hormone; TSH thyroid stimulating hormone, TG triglycerides,
FFAs free fatty acids, PP pancreatic polypeptide
a Six RA patients using corticosteroids were excluded from the analysis
bP values for Mann-Whitney U test (between RA patients and healthy controls)
cP values for Kruskal-Wallis test (between all the three groups)
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Previous studies have shown elevated levels of TG in
established RA patients [4, 5]. TG levels correlated posi-
tively with ESR in one study [17], although others could
not confirm this [7]. In our study, correlations between
TG levels and clinical and laboratory disease parameters
were found neither in RA patients nor in at-risk individ-
uals. Since TGs can be synthesized from FFAs and hydro-
lysis of TGs will release FFAs, it was interesting to mea-
sure the FFAs as well. In line with the findings for TGs, a
trend toward increased FFAs in at-risk individuals and
significantly higher levels in RA patients compared to
healthy controls were observed. Moreover, FFAs were
positively correlated with several clinical and laboratory
disease parameters in RA patients. The increased FFA
levels in established RA are in line with a previous report,
which also showed a positive correlation between FFA
and CRP levels. In that study, FFA levels were higher in
RA patients in the presence of the metabolic syndrome
[7]. The trend toward increased FFA levels during the
preclinical stage of RA described here is of interest in
light of another study in which we showed that obesity
is an independent risk factor for the development of RA in
subjects at risk of developing this disease based on their
autoantibody profile [13]. In an overweight or obese state,
the adipose tissue and even the number of adipocytes are
relatively increased. FFAs are released from adipocytes by
lipolysis of TGs [6]. Recently, it has been suggested that
FFAs could directly contribute to articular inflammation
and degradation in inflammatory joint diseases. In RA
synovial fibroblasts, FFAs dose-dependently enhanced
the secretion of IL-6, IL-8, and monocyte chemoattractant
protein 1 (MCP-1), as well as matrix metalloproteinase 1
(MMP1) and matrix metalloproteinase 3 (MMP3) [18].
These data suggest a possible role for FFAs in the patho-
genesis of RA, and it can be hypothesized that the in-
creased cardiovascular risk in the development of arthritis
might be partly explained by elevated production of FFAs
in obese RA patients.
The sympathetic nervous system may have an anti-
inflammatory effect during inflammation via the secretion of
catecholamines [19, 20]. The norepinephrine levels were sig-
nificantly higher in at-risk individuals, and there was a trend
toward higher levels in established RA patients compared to
healthy individuals, while epinephrine levels were similar be-
tween the groups. This may represent an attempt to control
inflammation.
Consistent with previous literature showing that basal pe-
ripheral blood levels of ACTH and cortisol are not different
between patients with chronic inflammatory diseases and
healthy controls [21, 22], we found similar levels of ACTH
and cortisol between the three groups. The hypothalamic-
pituitary-adrenal (HPA) axis response is relatively inadequate
in RA, which is reflected by a low cortisol/IL-6 ratio [23]. In
line with these findings, we demonstrated a trend toward low-
er cortisol/IL-6 ratios not only in established RA but also in
subjects at risk of developing RA.
Interestingly, the PP levels were significantly higher in both
at-risk individuals and RA patients compared to healthy con-
trols, although the PP levels did not correlate with clinical
Fig. 2 The TG levels in healthy controls, at-risk individuals, and patients
with early arthritis (validation cohort). a The serumTG levels were higher
in at-risk individuals and patients with early arthritis compared to healthy
controls. b The TG levels were significantly higher in at-risk individuals
who developed arthritis compared to individuals who did not develop
arthritis. One dot represents an individual and the median (interquartile
range) is plotted as a line in the middle. Kruskal-Wallis or Mann-Whitney
U test was used to detect differences in hormone levels between the
groups. *P < 0.05
Fig. 1 Hormones and peptides in healthy controls, at-risk individuals,
and patients with RA. The serum a epinephrine, b norepinephrine, c
adrenocorticotropic hormone (ACTH), d cortisol, e IL-6, f cortisol/IL-6
ratio, g estradiol, h follicle stimulating hormone (FSH), i luteinizing
hormone (LH), (j) prolactin (PRL), k growth hormone (GH), l thyroid
stimulating hormone (TSH), m triglycerides (TG), n free fatty acids
(FFAs), o glucagon, p glucose, q insulin, and r pancreatic polypeptide
(PP) level in healthy individuals, at-risk individuals, and patients with
RA. One dot represents an individual and the median (interquartile
range) is plotted as a line in the middle. Kruskal-Wallis test was used to
detect differences in hormone levels between the groups. * P < 0.05028
(after Bonferroni correction)
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disease parameters. The findings in established RA are in line
with previous work [8]. It has previously been hypothesized
that there may be a link between the gastrointestinal endocrine
axis and the immune system via an interaction between
proinflammatory cytokines and gut hormones. PYY, member
of the PP family, is one of the gut hormones, which could play
a (minor) role in RA [24]. It is conceivable that PP is more
important in the earliest phase of RA.
Fig. 3 FFA level correlated moderately with several clinical and
laboratory disease parameters in the RA patients. The correlations are
shown between FFAs and a visual analog scale for global disease
activity (VAS DA), b tender joint count 28 (TJC28), c swollen joint
count 28 (SJC28), d erythrocyte sedimentation rate (ESR, mm/Hr), e C-
reactive protein (CRP, mg/L) and disease activity score 28 (DAS28).One
dot represents an individual. Spearman’s rank-order correlation
coefficients were used to assess the correlations. * P < 0.05
Table 3 Baseline hormone/peptide levels in individuals developing arthritis
At risk for RA (n = 45)
baseline
At risk who did not developed
arthritis (n = 42) baseline
At risk who developed
arthritis (n = 3) baseline
P value At risk who developed arthritis
(n = 2) arthritis visit
Catecholamines
Epinephrine (nmol/L) 0.17 (0.06–0.26) 0.17 (0.06–0.27) 0.13 (0.03–0.19) 0.42 0.08 (0.03–0.12)
NE (nmol/L) 3.02 (2.24–4.15) 2.96 (2.42–4.20) 3.14 (1.70–3.50) 0.78 2.24 (1.85–2.62)
HPA axis response
ACTH (ng/L)a 19.2 (12.7–27.5) 19.3 (12.7–27.5) 13.1 (9.3–36.4) 0.65 23.7 (13.7–33.6)
Cortisol (nmol/L)a 323 (222–422) 341 (222–428) 279 (135–287) 0.12 304 (270–337)
IL-6 (pg/ml) 25.1 (3.8–54.5) 25.5 (2.1–54.5) 22.6 (18.1–163.3) 0.49 60.8 (30.6–91.0)
Cortisol/IL-6 ratioa 11.4 (5.3–35.1) 12.1 (5.3–40.9) 7.4 (1.7–12.7) 0.34 7.0 (3.0–11.0)
Sex hormones
Estradiol (nmol/L) 0.04 (0.02–0.08) 0.04 (0.02–0.08) 0.10 (0.02–0.42) 0.32 0.16 (0.08–0.24)
FSH (IU/L) 8.0 (3.2–71.7) 8.1 (3.2–71.7) 4.4 (1.6–107.9) 0.62 3.4 (3.0–3.8)
LH (IU/L) 7.1 (3.9–33.6) 7.8 (3.8–33.6) 4.3 (3.9–47.6) 0.95 4.6 (3.3–5.9)
Prolactin (μg/L) 9 (7–13) 9 (7–14) 8 (7–10) 0.63 9 (7–11)
Other hormones
GH (mU/L) 1.1 (0.50–3.20) 1.05 (0.30–3.70) 1.30 (1.10–2.20) 0.65 1.50 (1.40–1.60)
TSH (mU/L) 1.55 (1.25–2.50) 1.60 (1.30–2.40) 0.70 (0.59–2.60) 0.23 1.13 (0.55–1.70)
Peptides
TGs (mmol/L) 0.94 (0.72–1.15) 0.94 (0.71–1.15) 1.01 (0.90–1.38) 0.54 1.02 (0.78–1.25)
FFAs (mmol/L) 0.53 (0.40–0.59) 0.53 (0.40–0.61) 0.53 (0.37–0.55) 0.57 0.45 (0.42–0.49)
Glucagon (ng/L) 89 (74–99) 89 (71–99) 89 (76–95) 0.89 97 (95–99)
Glucose (mmol/L) 5.2 (4.8–5.4) 5.2 (4.8–5.4) 5.2 (5.0–5.8) 0.51 5.1 (5.0–5.5)
Insulin (pmol/L) 57 (43–100) 60 (43–103) 57 (35–73) 0.60 50 (26–73)
PP (pmol/L) 31 (21–45) 31 (21–41) 65 (6–112) 0.42 43 (6–80)
Data presented as median (interquartile range). P values forMann-Whitney U test for continuous variables. P < 0.05 is considered statistically significant
RA rheumatoid arthritis,NE norepinephrine,HPA axis response hypothalamic-pituitary-adrenal axis response, ACTH adrenocorticotropic hormone, IL-6
interleukin 6, FSH follicle stimulating hormone, LH luteinizing hormone, GH growth hormone, TSH thyroid stimulating hormone, TG triglycerides,
FFAs free fatty acids, PP pancreatic polypeptide. * 6 RA patients using corticosteroids were excluded from the analysis
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A limitation of this study is the relatively small sample size.
Of importance, however, the key results could be confirmed in an
independent cohort. A potential caveat in studies of hormone and
metabolic peptide levels is that theymay vary based on day-night
rhythm, fasting versus non-fasting state and gender. To address
this, we have used fasting serum samples, obtained at the same
time in the morning and corrected for gender in the analysis.
To our knowledge, this is the first study in which hormones
and metabolic peptides have been determined systemically in a
cohort of at-risk individuals, patients with RA, and healthy con-
trols in one study. Here, we show that especially FFA levels are
elevated in RA and correlate with disease activity. The data
support the notion that FFAs play an important role in the path-
ogenesis of RA in which they may contribute to the increased
risk of cardiovascular diseases. Further research of FFAs might
lead to the identification of new therapeutic targets for the treat-
ment and prevention of RA [25]. Furthermore, norepinephrine
and PP might be a new biomarker that may help to improve
prediction models in individuals at risk of developing RA.
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